RemeGen Co. Ltd

Detailed Description

RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of autoimmune diseases, such as systemic lupus erythematosus, neuromyelitis optica spectrum disorder, rheumatoid arthritis, IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; and Disitamab Vedotin (RC48) and RC98 for use in the treatment of various cancers. Its products in various stages of development include RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; RC108 that is in Phase 1 clinical trials to treat various solid tumors; and pre-clinical products, such as RC118, RC138, RC148, and RC158 to treat various solid tumors. The company was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.